Europe Insulin Syringes Market Size, Share & Industry Trends Analysis Report By Disease (Type 2 Diabetes and Type 1 Diabetes), By Syringe Size, By End User, By Country and Growth Forecast, 2021-2027

The Europe Insulin Syringes Market is expected to witness market growth of 3.7% CAGR during the forecast period (2021-2027).

The World Health Organization (WHO) wants to encourage and promote the implementation of efficient diabetes monitoring, preventive, and control methods, especially in low- and middle countries. WHO accomplishes this by developing scientific regarding the prevention of major noncommunicable diseases, such as diabetes; developing norms and standards for diabetes care and diagnosis; raising awareness of the global diabetes epidemic by commemorating World Diabetes Day (November 14); and conducting diabetes and risk factor surveillance.

Due to the surge in diabetes cases, companies are launching insulin syringes on a massive scale. For example, Abbott and Novo Nordisk today announced a non-exclusive cooperation to incorporate insulin dosage data from Novo Nordisk pre-filled and durable linked pens straight into digital health solutions compatible with the FreeStyle Libre system on February 20, 2019. Both firms are committed to making diabetes care easier by linking important technologies like continuous glucose monitoring (CGM) and linked insulin pens.

Diabetes is becoming more common among people of all ages in Europe, owing to rising rates of overweight and obesity, poor food, and physical inactivity. Cardiovascular illness (mainly heart disease and stroke) kills 50 percent of diabetics, whereas kidney failure kills 10-20 percent of diabetics. In the European Region, around 60 million individuals have diabetes, accounting for 10.3 percent of men and 9.6 percent of women aged 25 and above.

The Germany market dominated the Europe Insulin Syringes Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $137.9 million by 2027. The UK market is expected to showcase a CAGR of 2.9% during (2021 - 2027). Additionally, The France market is expected to witness a CAGR of 4.5% during (2021 - 2027).

Based on Disease, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Syringe Size, the market is segmented into 3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml) and Others. Based on End User, the market is segmented into Hospitals & Clinics, Homecare Settings, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Hindustan Syringes & Medical Devices Ltd., Novo Nordisk A/S, Biocon Limited, Eli Lilly and Company, Abbott Laboratories, Becton, Dickinson and Company, Cardinal Health, Inc., Medline Industries, Inc., Terumo Corporation, and Nipro Corporation.

Scope of the Study

Market Segments Covered in the Report:

By Disease

• Type 2 Diabetes and
• Type 1 Diabetes

By Syringe Size

• 3/10 CC Syringe (0.3ml)
• 1/2 CC Syringe (0.5ml)
• 1CC Syringe (1ml) and
• Others

By End User

• Hospitals & Clinics
• Homecare Settings, and
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Hindustan Syringes & Medical Devices Ltd.
• Novo Nordisk A/S
• Biocon Limited
• Eli Lilly and Company
• Abbott Laboratories
• Becton, Dickinson and Company
• Cardinal Health, Inc.
• Medline Industries, Inc.
• Terumo Corporation
• Nipro Corporation

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free